Company: RNGE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024206
Chunk: 149

Company: RANGE IMPACT, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part II, Item 8
Chunk 149
---
 of the
following three categories.

    ●
    Level
    1:
    Quoted
    market prices in active markets for identical assets or liabilities

    ●
    Level
    2:
    Inputs
    to the valuation methodology include:

    ○
    Quoted
    prices for similar assets or liabilities in active markets;

    ○
    Quoted
    prices for identical assets or similar assets or liabilities in inactive markets;

    ○
    Inputs
    other than quoted prices that are observable for the asset or liability;

    ○
    Inputs
    that are derived principally from or corroborated by observable market data by correlation or other means.

    ●
    Level
    3:
    Unobservable
    inputs that are not corroborated by market data

A
financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
to the fair value measurement.

The
following is a description of the valuation methodologies used for instruments measured at fair value, including the general classification
of such instruments pursuant to the valuation hierarchy.

The
equipment held for sale is carried at the lower of carrying amount or fair value, and is considered level 2 as it is based on market
prices for similar assets.

    13

Segments

As
of June 30, 2025, the Company has two operating business segments: (i) Range Land and (ii) Range Services. The Fola Mine, including the
royalty and lease agreements assigned in connection with the Fola Acquisition, and the Hobet Mine are reported in the Range Land operating
business segment. Effective January 1, 2025, the business activities of the Range Reclaim, Range Security and Range Water operating business
segments, which had been previously-reported as separate operating business segments, are now captured as part of the Range Services
operating business segment. This change was implemented as each of these business segments now serve to support the reclamation and improvement
of the land holdings of Range Land and not as businesses serving other customers. The change in the segment reporting is shown retrospectively
in this filing. Graphium Biosciences was sold in September 2024 and therefore the drug development business segment named Graphium Biosciences
is no longer reported as an operating business segment of the Company.

In
accordance with the “Segment Reporting” Topic of the ASC 280, the Company’s chief operating decision-maker has been
identified as the